Assessment of socioeconomic impact of rheumatological care to patients with temporary work disability of musculoskeletal origin

Recruitment status No longer recruiting	Prospectively registered		
	☐ Protocol		
Overall study status Completed	Statistical analysis plan		
	[X] Results		
Condition category	[] Individual participant data		
	No longer recruiting Overall study status Completed		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Juan Angel Jover

Contact details

Servicio de Reumatología Hospital Clínico San Carlos C/ Martín Lagos, s/n Madrid Spain 28040 +34 91 330 36 15 jjover.hcsc@salud.madrid.org

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

FIS 98/1050

Study information

Scientific Title

Acronym

IT-ME-98

Study objectives

A population-based, clinical program offered to patients with recent-onset work disability caused by Musculoskeletal Disorders (MSDs) is cost-effective with respect to standard care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study protocol was approved by the institutional review board of the Hospital Clínico San Carlos and reviewed by the Fondo de Investigaciones Sanitarias (the research agency of the Ministry of Health). Date of approval June 2, 1998.

Study design

Randomized, controlled study, unblinded for both patients and physicians, of two years duration (recruitment one year, follow-up one year)

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Musculoskeletal disorders causing temporary work disability.

Interventions

The intervention was a specific clinical program. The control group received standard care.

At the first 45-minute visit, patients received a specific diagnosis, reassurance that no serious disease was present, instructions on self-management, instructions on taking medications on a fixed schedule, and information on indications for return to work before complete symptom

remission. Return to work was negotiated with patients and was never forced on them. Instructions on self-management included instructions to avoid bed rest, instructions to promote early mobilization of the painful regions, restrictions on the use of splint and neck collars, training in stretching and strengthening exercises, teaching of ergonomic care, delivery of booklets in instances of back or neck pain, and information on optimal levels of physical activity. Patients with higher degrees of disability or abnormal pain behavior received immediate extra reassurance, information on pain-relieving positions, and a telephone call or second visit within 72 hours.

Specific protocols were created for low-back, neck, shoulder, arm and hand, knee, and foot pain and included the three-level clinical-management system described below. Moving a patient from the lower to the upper levels of the system implied the need for further diagnostic or therapeutic procedures and was indicated 1) after a patient spent a predefined period at the lower level without return to work or substantial clinical improvement or 2) by the clinical judgment of the rheumatologist.

At the first level of the system, patients received the clinical management started at the first visit, including a diagnosis based on clinical criteria, pharmacologic treatment of pain and inflammation, pharmacologic treatment of anxiety and depression, peripheral intra- and periarticular injections, and education. Time spent at the first level averaged 2 to 6 weeks. At the second level, patients received maintenance of therapy plus referral for formal rehabilitation and laboratory tests, radiography, computerized tomography, magnetic resonance imaging, and electromyography. After 4 to 8 weeks with no improvement at the second level, patients were moved to the third level and received further diagnostic procedures or referral for surgical or other specialized care. Red flags were defined, including age greater than 50 years for patients with axial pain, previous trauma, cancer, serious medical illness, inflammatory pain, night pain, drug abuse, corticosteroid use, fever, weight loss, progressively deteriorating function, and progressive neurologic deficit. The presence of a red flag precluded the use of the level system, and the patient in question was managed according to clinical criteria, with a focus on excluding serious illness.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Efficacy was defined as the differences between groups in the following:

- 1. Duration of all episodes of MSD-related temporary work disability
- 2. Number of episodes of MSD-related temporary work disability per patient, assessed one year after the end of inclusion period
- 3. Number and outcome of proposals for permanent work disability

Secondary outcome measures

- 1. Relative efficacy is expressed as the percentage of days on temporary work disability saved per patient and as the total number of days on temporary work disability saved in the intervention group (number of episodes in the intervention group x [mean duration of episodes in control group mean duration of episodes in intervention group]).
- 2. Cost-efficacy was defined as the amount of money required to save 1 day of temporary work disability.

3. Cost-benefit was defined as dollars invested divided by dollars saved. Net benefit was defined as dollars saved minus dollars invested.

Overall study start date

01/03/1998

Completion date

01/03/2001

Eligibility

Key inclusion criteria

The issue of a common diseases temporary work disability initiation form, with an MSD-related cause reported by the primary care physician. The MSD-related causes included the following:

- 1. All arthropathies
- 2. Connective tissue disorders
- 3. Back disorders
- 4. Soft-tissue rheumatisms
- 5. Bone and cartilage disorders
- 6. Musculoskeletal pain not caused by cancer
- 7. Nerve entrapment syndromes

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

13077 (7805 in control group and 5272 in intervention group)

Key exclusion criteria

- 1. Patients who had common diseases temporary work disability form with an MSD-related cause resulting from trauma or surgery.
- 2. Patients who had work accidents or professional diseases noted on the temporary work disability initiation form. Work accidents are primarily sudden, external, violent causes of disease occurring at work or during travel to work, and they represent less than 27% of cases of temporary work disability. Professional diseases include silicosis, asbestos-related mesotelioma, and noise-induced hearing loss, and they represent less than 1% of cases of temporary work disability.

Date of first enrolment

01/03/1998

Date of final enrolment

01/03/2001

Locations

Countries of recruitment

Spain

Study participating centre Servicio de Reumatología

Madrid Spain 28040

Sponsor information

Organisation

The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain)

Sponsor details

C/ Sinesio Delgado N° 6 (Pabellón N° 4) Madrid Spain 28029 +34 91 822 21 00 Oficina.informacion@isciii.es

Sponsor type

Government

Website

http://www.isciii.es/htdocs/en/investigacion/investigacion_presentacion.jsp

ROR

https://ror.org/00ca2c886

Funder(s)

Funder type

Government

Funder Name

Research Funding Agency of the Spanish Ministry of Health (Fondo de Investigación Sanitaria; FIS)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results:	20/09/2005		Yes	No
Results article	Results:	15/03/2007		Yes	No